MIT and Recursion have released Boltz-2, the first biomolecular co-folding model that simultaneously predicts molecular structure and binding affinity with remarkable accuracy, approaching that of ...

Using its capital, Recursion is in Phase I clinical trials for the treatment of CCM, the problem Gibson was studying when he had the epiphany about cell painting and big data.